Newsletter

Stay up to date on all things atrial fibrillation. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

January 24, 2020

Overview

The goal of this study is to determine the long term success of non-paroxysmal ablation to treat atrial fibrillation using three different approaches: specified low voltage-directed with pulmonary vein isolation, empiric posterior wall isolation with pulmonary vein isolation and an approach of pulmonary vein isolation (PVI) alone. During the trial, patients will be monitored with implantable loop recorders and attend a follow-up appointment one year after participating in the trial.

 

Study Information

303 subjects will be enrolled in the study. The primary purpose of the trial is treatment. The study began on February 14, 2017 and is estimated to be completed by January 2021.

 

Inclusion Criteria

 

  • Non-Paroxysmal Atrial Fibrillation.
  • Failed or intolerable to at least 1 one antiarrhythmic drug (AAD).
  • 18-85 year of age at the time of consent.
  • Able and willing to comply with all protocol visit requirements.
  • Signed Patient Informed Consent (ICF).

 

Exclusion Criteria

 

  • History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE.
    • Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV node reentry tachycardia or focal ectopic atrial tachycardia may be included.
  • Uncontrolled heart Failure or NYHA Class IIIb or IV heart failure.
  • Ejection Fraction < 0.20.
  • Active ventricular tachycardia requiring treatment with catheter ablation or anti-arrhythmic drug within the last 6 months.
  • Left atrial size > 60 mm diameter on echocardiogram.
  • “Long standing” persistent AF defined as > or = 1 year of continuous atrial fibrillation at the time of enrollment.
  • Severe pulmonary hypertension (PAP > 70 mmHg)
  • AF secondary to electrolyte imbalance, thyroid disease or reversible non- cardiac cause.
  • Poor candidate for general anesthesia.
  • Anticipated survival < 1 year.
  • MI or CABG within 3 months.
  • Left atrial thrombus in pre-procedure imaging within 4 weeks of the ablation procedure.
  • Any documented thromboembolic event within 6 months of the ablation procedure.
  • Contraindication to anticoagulation.
  • Inability to have implantable monitoring devices for atrial fibrillation burden with no pre-existing cardiac device that can monitor atrial arrhythmias.
  • Significant congenital anomaly or medical condition that may affect the integrity of study data.
  • Women who are pregnant – pregnancy test required if pre-menopausal or non-sterile.
  • Active enrollment in another investigational study involving a drug or device.
  • Inability to undergo complete voltage mapping in normal sinus rhythm – see intraprocedural protocol.

 

Location

The study will take place at the MetroHealth Medical Center, Cleveland, Ohio, United States, 44109. If you have any questions, please contact Peter Leo BS, RN at 216-778-2714 / pleo@metrohealth.org.

 

Sponsors / Collaborators

This study is sponsored by Ohad Ziv and Biosense Webster, Inc. The principal investigator is Ohad Ziv, MD of the MetroHealth System.

View All Clinical Trials

Clinical Trials

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

This study aims to survey patients with atrial fibrillation in order to understand direct-acting oral anticoagulant (DOAC) treatment from the…

iCLAS for Persistent Atrial Fibrillation

This study aims to evaluate the safety of the Adagio AF Cryoablation System (iCLAS™) for ablation treatment of persistent atrial fibrillation.…

Esophageal Deviation in Atrial Fibrillation Ablation

Ablation treatment in the posterior wall of the left atrium can cause thermal injury to the esophagus, which is a very common occurrence. The goal…

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter

The goal of this study is to compare heart rate control (heart rate <110 beats per minute) at 2 hours after taking the medication diltiazem…

The Genetic Basis for Atrial Fibrillation

Veteran patients with atrial fibrillation will be examined for common genetic polymorphisms, and identify…

Liraglutide Effect in Atrial Fibrillation

The goal of this study is to use a medication called Liraglutide to reduce fat deposits surrounding the heart, and…

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

The goal of this study is to see how electrogram morphology recurrence (EMR) mapping works on patients with atrial…

High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation

The goal of the study is to find a correlation between FIRM targeted sites and micro-anatomic fibrotic tracks. Patients will first undergo a…

Send this to a friend